Dova Pharmaceuticals Inc logo

DOVA - Dova Pharmaceuticals Inc News Story

$28.04 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £9.83m
Position in Universe th / 6858

BUZZ-Dova: Leerink downgrades; raises concerns with blood disorder drug

Mon 9th July, 2018 1:23pm
** Leerink downgrades the drug developer's stock  DOVA.O  to
"market perform" from "outperform"
    ** Cuts PT by $2 to $33, a 13 pct upside to stock's last
close; median PT at $37
    ** Dova's stock has performed strongly since the approval of
Doptelet, the co's first and only product for treating low blood
platelet count in patients with chronic liver disease (CLD) -
Leerink
    ** DOVA up ~20 pct since it announced the approval of
Doptelet in May  urn:newsml:reuters.com:*:nL3N1SS4HH
    ** Drug's higher than expected pricing is a surprise and
raises concerns about the commercial prospects for the drug
    ** Upon research on the product's price, label, eligible
patient population and likely use, the brokerage found that the
immediate addressable patient population will be only a small
fraction of the theoretical pool of such patients
    ** Brokerage notes other barriers to Doptelet's use include
patient identification and qualification, scheduling logistics,
reimbursement access among other things
    ** All these issues can be solved, but it seems likely that
it will take many quarters before significant recurring
treatment volume can be expected - Leerink
    ** DOVA dips 1 pct to $28.90 premarket; has gained 1.4 pct
this year

 (Reporting by Medha Singh in Bengaluru)
 ((medha.singh@thomsonreuters.com))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.